Motif Bio’s Antibiotic Resistant Drug and Stock Turnaround

Motif Bio stock is a high risk, high reward gambit on iclaprim, an antibiotic drug that can kill antibiotic resistant bacteria.

Summary

  • Motif Bio has developed a bacteria killer using a new approach that could help the drug overcome antibiotic resistance.
  • Iclaprim had solid Phase 3 trial data that demonstrated non-inferiority for all primary endpoints.
  • Large players volume is rising.
  • This is a high, risk high reward gambit.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Author: Lance Jepsen

    For ethical purposes, I try not to hold any position in any stock I profile on GuerillaStockTrading.com unless specifically stated in the article. Owner of GuerillaStockTrading.com. Seasoned entrepreneur, investor, and writer. I love God, family, country, stock trading, economics, and helping people learn how to trade.

    Leave a Reply

    Sending